Fir (Shenzhen) Biotechnology Co., Ltd. has announced the successful completion of a Pre-A+ funding round, raising tens of millions of dollars from investors including funds managed by several professors and Pine Capital. The funds secured will primarily be allocated towards refining the company's shareholding structure, scaling up production, and ensuring market readiness, thereby accelerating the deployment of "AI family medical robots." Fir Biotechnology's flagship product is the fully automated micro medical robot, dubbed the "Perception Series," which leverages AI technology to perform multi-index quantitative analysis, offer health recommendations, create personalized digital health twins for users, and facilitate the transition from reactive disease treatment to proactive health management. This funding success underscores the growing recognition and momentum in the "AI + family healthcare" sector.